Insight Molecular Diagnostics FY2025 revenue rises 115.79% to $4.1 million; operating expenses climb 37% to $53.4 million

Reuters

Yesterday

Insight Molecular Diagnostics FY2025 revenue rises 115.79% to $4.1 million; operating expenses climb 37% to $53.4 million

iMDx published a shareholder letter alongside its fourth-quarter and full-year 2025 financial results, reporting full-year revenue of USD 4.1 million, up 115.8% year over year.
Fourth-quarter revenue was USD 1.1 million, with gross profit of USD 496,000 and gross margin of 43.5%.
Operating expenses in the quarter were USD 23.9 million, including USD 14.6 million of non-cash intangible asset impairment losses.
Net loss for the quarter was USD 23.0 million, or USD 0.72 per share, while adjusted net loss was USD 8.7 million, or USD 0.27 per share.
Management said it submitted the GraftAssureDx kidney transplant rejection test for FDA review and is planning for an FDA-authorized product this year, while guiding to average cash burn of about USD 7.5 million per quarter in 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insight Molecular Diagnostics Inc. published the original content used to generate this news brief on March 26, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2622466896"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2622466896\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2622466896?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-27 04:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622466896","market":"fut","top_or_hot":-1,"title":"Insight Molecular Diagnostics FY2025 revenue rises 115.79% to $4.1 million; operating expenses climb 37% to $53.4 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Insight Molecular Diagnostics FY2025 revenue rises 115.79% to $4.1 million; operating expenses climb 37% to $53.4 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          iMDx published a shareholder letter alongside its fourth-quarter and full-year 2025 financial results, reporting full-year revenue of USD 4.1 million, up 115.8% year over year.\n        </li>\n<li>\n          Fourth-quarter revenue was USD 1.1 million, with gross profit of USD 496,000 and gross margin of 43.5%.\n        </li>\n<li>\n          Operating expenses in the quarter were USD 23.9 million, including USD 14.6 million of non-cash intangible asset impairment losses.\n        </li>\n<li>\n          Net loss for the quarter was USD 23.0 million, or USD 0.72 per share, while adjusted net loss was USD 8.7 million, or USD 0.27 per share.\n        </li>\n<li>\n          Management said it submitted the GraftAssureDx kidney transplant rejection test for FDA review and is planning for an FDA-authorized product this year, while guiding to average cash burn of about USD 7.5 million per quarter in 2026.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/IMDX\">Insight Molecular Diagnostics Inc.</a> published the original content used to generate this news brief on March 26, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Insight Molecular Diagnostics FY2025 revenue rises 115.79% to $4.1 million; operating expenses climb 37% to $53.4 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInsight Molecular Diagnostics FY2025 revenue rises 115.79% to $4.1 million; operating expenses climb 37% to $53.4 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-27 04:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Insight Molecular Diagnostics FY2025 revenue rises 115.79% to $4.1 million; operating expenses climb 37% to $53.4 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          iMDx published a shareholder letter alongside its fourth-quarter and full-year 2025 financial results, reporting full-year revenue of USD 4.1 million, up 115.8% year over year.\n        </li>\n<li>\n          Fourth-quarter revenue was USD 1.1 million, with gross profit of USD 496,000 and gross margin of 43.5%.\n        </li>\n<li>\n          Operating expenses in the quarter were USD 23.9 million, including USD 14.6 million of non-cash intangible asset impairment losses.\n        </li>\n<li>\n          Net loss for the quarter was USD 23.0 million, or USD 0.72 per share, while adjusted net loss was USD 8.7 million, or USD 0.27 per share.\n        </li>\n<li>\n          Management said it submitted the GraftAssureDx kidney transplant rejection test for FDA review and is planning for an FDA-authorized product this year, while guiding to average cash burn of about USD 7.5 million per quarter in 2026.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/IMDX\">Insight Molecular Diagnostics Inc.</a> published the original content used to generate this news brief on March 26, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MDIT","symbol_name":"Medite Cancer Diagnostics, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL7Y4TcY:1","article_id":"2622466896","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622466896","pubTimestamp":1774555787,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"iMDx published a shareholder letter alongside its fourth-quarter and full-year 2025 financial results, reporting full-year revenue of USD 4.1 million, up 115.8% year over year.Fourth-quarter revenue was USD 1.1 million, with gross profit of USD 496,000 and gross margin of 43.5%.Operating expenses in the quarter were USD 23.9 million, including USD 14.6 million of non-cash intangible asset impairment losses.Net loss for the quarter was USD 23.0 million, or USD 0.72 per share, while adjusted net loss was USD 8.7 million, or USD 0.27 per share.Management said it submitted the GraftAssureDx kidney transplant rejection test for FDA review and is planning for an FDA-authorized product this year, while guiding to average cash burn of about USD 7.5 million per quarter in 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purpo","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MDIT":"Medite Cancer Diagnostics, Inc.","BK4082":"医疗保健设备","BK4139":"生物科技","IMDX":"Insight Molecular Diagnostics Inc."},"translate_title":"Insight Molecular Diagnostics 2025财年收入增长115.79%至410万美元；运营费用攀升37%至5,340万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IMDX":0.9,"MDIT":0.9},"content_text":"Insight Molecular Diagnostics FY2025 revenue rises 115.79% to $4.1 million; operating expenses climb 37% to $53.4 million\n    \n\n\n          iMDx published a shareholder letter alongside its fourth-quarter and full-year 2025 financial results, reporting full-year revenue of USD 4.1 million, up 115.8% year over year.\n        \n\n          Fourth-quarter revenue was USD 1.1 million, with gross profit of USD 496,000 and gross margin of 43.5%.\n        \n\n          Operating expenses in the quarter were USD 23.9 million, including USD 14.6 million of non-cash intangible asset impairment losses.\n        \n\n          Net loss for the quarter was USD 23.0 million, or USD 0.72 per share, while adjusted net loss was USD 8.7 million, or USD 0.27 per share.\n        \n\n          Management said it submitted the GraftAssureDx kidney transplant rejection test for FDA review and is planning for an FDA-authorized product this year, while guiding to average cash burn of about USD 7.5 million per quarter in 2026.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insight Molecular Diagnostics Inc. published the original content used to generate this news brief on March 26, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}